The SK-N-SH cell line was isolated in 1970 from the brain tissue extracted from a 4-year-old female patient suffering from a neuroblastoma. These cells are ideal as transfection hosts because they are known to express high levels of dopamine-beta-hydroxylase and having a higher doubling time. SK-N-SH are used in biomedical research for certain types of brain cancer. Altogen Biosystems manufactures and prepares a SK-N-SH transfection reagent that is cationic lipid based with a high transfection efficacy. This reagent is proven to establish stable cell lines for reliable yields.
The SK-N-SH cell line was established in 1970 from the bone marrow metastasis of a 4-year-old female with neuroblastoma. SK-N-SH cells exhibit an epithelial morphology and adherent cultural properties. SK-N-SH is capable of differentiating and exhibiting neurite outgrowths. This hyperdiploid cell line has a modal chromosome number of 47 and is genetically female with two X chromosomes. SK-N-SH cells express blood type A and Rh+ , as well as produce high levels of dopamine-beta-hydroxylase. Pediatric brain cancer is one of the leading causes of cancer-related deaths in children under 20 years old, and neuroblastoma cell lines like SK-N-SH are valuable tools in preclinical research that allow scientists to develop new drugs and treatments. A pre-optimized SK-N-SH transfection reagent to transfect SK-N-SH cells and conduct brain cancer research is commercially available from Altogen Biosystems . SK-N-SH cells can also be used to study neural pathways. Past studies h...